Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) – Pipeline Review, H2 2016’, provides in depth analysis on Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted pipeline therapeutics.

The report provides comprehensive information on the Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)

The report reviews Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects

The report assesses Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

American Gene Technologies International Inc.

AstraZeneca Plc

BeiGene, Ltd.

Clovis Oncology, Inc.

Eisai Co., Ltd.

Hager Biosciences, LLC

IMPACT Therapeutics, Inc.

Jeil Pharmaceutical Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Mitsubishi Tanabe Pharma Corporation

Nerviano Medical Sciences S.r.l.

Takeda Pharmaceutical Company Limited

Tesaro, Inc.

Teva Pharmaceutical Industries Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) Overview 9

Therapeutics Development 10

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Products under Development by Stage of Development 10

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Products under Development by Therapy Area 11

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Products under Development by Indication 12

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Pipeline Products Glance 14

Late Stage Products 14

Early Stage Products 15

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Products under Development by Companies 16

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Products under Development by Universities/Institutes 22

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Therapeutics Assessment 24

Assessment by Monotherapy/Combination Products 24

Assessment by Mechanism of Action 25

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Companies Involved in Therapeutics Development 30

AbbVie Inc 30

American Gene Technologies International Inc. 31

AstraZeneca Plc 32

BeiGene, Ltd. 33

Clovis Oncology, Inc. 34

Eisai Co., Ltd. 35

Hager Biosciences, LLC 36

IMPACT Therapeutics, Inc. 37

Jeil Pharmaceutical Co., Ltd. 38

Jiangsu Hengrui Medicine Co., Ltd. 39

Mitsubishi Tanabe Pharma Corporation 40

Nerviano Medical Sciences S.r.l. 41

Takeda Pharmaceutical Company Limited 42

Tesaro, Inc. 43

Teva Pharmaceutical Industries Ltd. 44

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Drug Profiles 45

ABT-767 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

AG-PD - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

AZ-0108 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

AZD-1775 + olaparib - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

BGB-290 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

CK-102 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

E-7449 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

fluzoparib - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

IMP-04297 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

JPI-289 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

MP-124 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

niraparib - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

NMSP-118 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

NMSP-648 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

NMSP-914 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

olaparib - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

R-554 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

rucaparib camsylate - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

SC-10914 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Small Molecule to Inhibit PARP-1 for Undisclosed Indication - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Small Molecules to Inhibit PARP-1 for Colorectal Cancer - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

veliparib - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

XZ-120312 - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

YHP-743 - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Dormant Projects 98

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Discontinued Products 103

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC

2.4.2.30) - Featured News & Press Releases 104

Oct 26, 2016: Lynparza Phase III SOLO-2 trial shows significant progression-free survival benefit 104

Oct 26, 2016: Myriad's BRACAnalysis CDx Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib 104

Oct 08, 2016: DNA Repair-Blocking Drug Substantially Improves Progression Free survival for Common Form of Recurrent Ovarian Cancer, International Trial Finds 105

Oct 08, 2016: Myriad's myChoice HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib 106

Oct 08, 2016: TESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016 107

Oct 07, 2016: Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress 109

Sep 28, 2016: Clovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress 112

Sep 12, 2016: TESARO Receives FDA Fast Track Designation for Niraparib and Initiates Rolling NDA Submission 112

Sep 06, 2016: TESARO To Present Phase 3 Results From ENGOT-OV16/NOVA Trial of Niraparib at the 2016 European Society for Medical Oncology Annual Meeting 113

Sep 05, 2016: A Gene Defect as a Potential Gateway for Targeted Prostate Cancer Therapy 113

Aug 23, 2016: FDA Accepts Clovis Oncology’s New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer 114

Jul 08, 2016: ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial 115

Jul 08, 2016: Loyola Oncologist Co-authors Veliparib plus Carboplatin Study That Used New, Targeted Model to Test Breast Cancer Treatment 117

Jun 29, 2016: Myriad myChoice HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO Pivotal Phase 3 Ovarian Cancer Study with Niraparib 118

Appendix 119

Methodology 119

Coverage 119

Secondary Research 119

Primary Research 119

Expert Panel Validation 119

Contact Us 119

Disclaimer 120

List of Tables

List of Tables

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 (Contd..1) 18

Products under Development by Companies, H2 2016 (Contd..2) 19

Products under Development by Companies, H2 2016 (Contd..3) 20

Products under Development by Companies, H2 2016 (Contd..4) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Products under Investigation by Universities/Institutes, H2 2016 23

Assessment by Monotherapy/Combination Products, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Pipeline by AbbVie Inc, H2 2016 30

Pipeline by American Gene Technologies International Inc., H2 2016 31

Pipeline by AstraZeneca Plc, H2 2016 32

Pipeline by BeiGene, Ltd., H2 2016 33

Pipeline by Clovis Oncology, Inc., H2 2016 34

Pipeline by Eisai Co., Ltd., H2 2016 35

Pipeline by Hager Biosciences, LLC, H2 2016 36

Pipeline by IMPACT Therapeutics, Inc., H2 2016 37

Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 38

Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 39

Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 40

Pipeline by Nerviano Medical Sciences S.r.l., H2 2016 41

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 42

Pipeline by Tesaro, Inc., H2 2016 43

Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 44

Dormant Projects, H2 2016 98

Dormant Projects (Contd..1), H2 2016 99

Dormant Projects (Contd..2), H2 2016 100

Dormant Projects (Contd..3), H2 2016 101

Dormant Projects (Contd..4), H2 2016 102

Discontinued Products, H2 2016 103

List of Figures

List of Figures

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Top 10 Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 28

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared